CareDx (NASDAQ:CDNA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

CareDx (NASDAQ:CDNA) had its target price raised by Wells Fargo & Company from $18.00 to $21.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 14.42% from the stock’s previous close.

A number of other analysts have also recently commented on CDNA. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Zacks Research raised shares of CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. Wall Street Zen lowered shares of CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research report on Monday, December 29th. Finally, BTIG Research boosted their price objective on CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, CareDx has a consensus rating of “Hold” and an average target price of $27.17.

CareDx Price Performance

NASDAQ CDNA traded down $0.90 during midday trading on Wednesday, hitting $18.35. 448,972 shares of the company traded hands, compared to its average volume of 704,670. The company has a market cap of $943.95 million, a PE ratio of 15.05 and a beta of 2.51. CareDx has a 52 week low of $10.96 and a 52 week high of $22.95. The company’s 50-day simple moving average is $19.68 and its 200-day simple moving average is $16.74.

CareDx (NASDAQ:CDNA) last posted its earnings results on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The firm had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The company’s revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.18 EPS. On average, research analysts predict that CareDx will post -0.9 earnings per share for the current year.

Insider Activity

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at $12,641,089.80. This represents a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 29,636 shares of company stock worth $625,949. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

A number of hedge funds have recently bought and sold shares of the business. Bamco Inc. NY raised its stake in shares of CareDx by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company’s stock worth $45,876,000 after buying an additional 719,523 shares during the period. State Street Corp increased its holdings in CareDx by 6.7% in the 4th quarter. State Street Corp now owns 2,737,752 shares of the company’s stock worth $51,579,000 after acquiring an additional 171,303 shares in the last quarter. Deerfield Management Company L.P. acquired a new position in CareDx during the third quarter worth $31,857,000. Braidwell LP purchased a new position in CareDx during the third quarter valued at $31,738,000. Finally, ARK Investment Management LLC grew its position in shares of CareDx by 3.4% in the third quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company’s stock valued at $31,561,000 after purchasing an additional 70,468 shares during the period.

Key CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: Q4 revenue topped Street estimates and showed robust year‑over‑year growth (quarterly revenue ~$108.4M, ~25% YoY), supporting the company’s top‑line momentum. CareDx Q4 2025 Highlights
• Positive Sentiment: Management updated FY‑2026 revenue guidance to a range (~$420M–$444M) that sits above consensus (~$417.5M), which likely helped sentiment despite the EPS miss.
• Positive Sentiment: Leadership move: COO Keith Kennedy will also assume CFO responsibilities, giving investors clarity on finance leadership during the transition. BusinessWire: CFO Appointment
• Neutral Sentiment: Company released the full earnings presentation and call transcript/slides — useful for modeling but not market-moving by itself. Earnings Presentation
• Negative Sentiment: Q4 EPS missed consensus: reported $0.12 vs. consensus ~$0.24, which disappointed earnings-focused investors and pressured margins/earnings durability questions. Zacks: Q4 Earnings Miss
• Negative Sentiment: Some transcripts/reporting show conflicting EPS figures (one transcript cites an adjusted/GAAP discrepancy with a negative EPS figure), adding short‑term uncertainty around reported metrics and adjustments. Earnings Call Transcript

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.